Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1997 1
2003 3
2004 1
2005 1
2007 1
2009 3
2010 4
2011 6
2012 6
2013 8
2014 13
2015 12
2016 15
2017 21
2018 19
2019 31
2020 30
2021 31
2022 31
2023 30
2024 32
2025 38
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

280 results

Results by year

Filters applied: . Clear all
Page 1
Antidiabetic Medications and Bladder Cancer Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Rao Y, Meng S, Yu EY, Chen Y, van Alebeek R, Al-Zalabani AH, Zeegers MP, Wesselius A. Rao Y, et al. Among authors: yu ey. Endocr Pract. 2025 Dec 17:S1530-891X(25)01328-X. doi: 10.1016/j.eprac.2025.11.017. Online ahead of print. Endocr Pract. 2025. PMID: 41419174 Free article. Review.
OBJECTIVE: The long-term safety of antidiabetic medications, particularly their potential association with bladder cancer (BC), remains a concern in type 2 diabetes mellitus (T2DM) management. METHODS: We conducted a systematic review and meta-analysis of randomized …
OBJECTIVE: The long-term safety of antidiabetic medications, particularly their potential association with bladder cancer (BC) …
Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations.
Cheng HH, Callis S, Yu EY, Delacroix SE, Sokolova AO, Tangen CM, Lerner SP, Dorff TB, Lin DW. Cheng HH, et al. Among authors: yu ey. Eur Urol Focus. 2025 Dec 6:S2405-4569(25)00343-8. doi: 10.1016/j.euf.2025.11.011. Online ahead of print. Eur Urol Focus. 2025. PMID: 41354605
SWOG S2210 is a phase 2 trial testing the use of biomarker-guided neoadjuvant carboplatin, a safe and accessible chemotherapy agent, for patients with localized high-risk prostate cancer and inherited BRCA1/2 mutations. The endpoints are pathologic complete response rates …
SWOG S2210 is a phase 2 trial testing the use of biomarker-guided neoadjuvant carboplatin, a safe and accessible chemotherapy agent, for pat …
Integration of gut microbiome and lipid metabolism reveals the anti-cancer effects of pentadecanoic acid on bladder cancer.
Chen YT, Sui J, Yang Y, Zhang H, Wesselius A, Shen Y, Qin QR, Sun GJ, Wang SK, Wang XD, Wang S, Li WC, Cheng KK, James ND, Bryan RT, Zeegers MP, Chen L, Xia H, Yu EY. Chen YT, et al. Among authors: yu ey. BMC Med. 2025 Dec 3;24(1):10. doi: 10.1186/s12916-025-04554-5. BMC Med. 2025. PMID: 41339867 Free PMC article.
BACKGROUND: Pentadecanoic acid (PEA), an odd-chain fatty acid derived from diet by the gut microbiome, has garnered increasing attention for its systemic health-promoting properties. Its potential role in bladder cancer (BC) occurrence and invasion, however, remains …
BACKGROUND: Pentadecanoic acid (PEA), an odd-chain fatty acid derived from diet by the gut microbiome, has garnered increasing attention for …
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis.
Yu EY, Suzuki H, Pieczonka CM, Gotto G, Briganti A, Luz M, Murphy D, Malone R, Hamilton J, Chan JE, Sieber P, Given RW, Hellmis E, Kretz T, Spiegelhalder P, Gómez-Caamaño A, Amela YM, Artignan X, Uemura H, Fujita N, Adorjan P, Ghadessi M, Verholen F, Armstrong AJ. Yu EY, et al. Prostate Cancer Prostatic Dis. 2025 Nov 1. doi: 10.1038/s41391-025-01047-7. Online ahead of print. Prostate Cancer Prostatic Dis. 2025. PMID: 41176520
BACKGROUND: DAROL is an ongoing study of real-world safety and effectiveness of darolutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). SUBJECTS/METHODS: This prespecified interim analysis included 550 patients with nmCRPC who completed 6 …
BACKGROUND: DAROL is an ongoing study of real-world safety and effectiveness of darolutamide in patients with nonmetastatic castration-resis …
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.
Einstein DJ, Abel ML, Aragon-Ching JB, Arlen PM, Autio KA, Bilusic M, Carducci MA, Choyke PL, Citrin DE, Figg WD, Graff JN, Gulley JL, Halabi S, Karzai F, Lindenberg L, Markowski MC, Marshall CH, McNeel DG, Mena E, Moon H, Pachynski RK, Paller CJ, Patel KR, Posadas EM, Pienta KJ, Regan MM, Sena LA, Walmsley CS, Wei XX, Yu EY, Tran PT, Madan RA. Einstein DJ, et al. Among authors: yu ey. J Clin Oncol. 2025 Dec;43(34):3672-3683. doi: 10.1200/JCO-25-01693. Epub 2025 Oct 23. J Clin Oncol. 2025. PMID: 41129763
PURPOSE: Biochemical recurrence (BCR) of prostate cancer (PCa) after definitive surgery and/or radiation (including salvage strategies) is a burgeoning area of clinical research inspired by ultrasensitive next-generation imaging. ...The WG suggested defining high-risk BCR …
PURPOSE: Biochemical recurrence (BCR) of prostate cancer (PCa) after definitive surgery and/or radiation (including salvage strategie …
Drug Targets in Prostate Cancer: An Appetite for KLK2-Mediated Destruction.
Blinka S, Yu EY. Blinka S, et al. Among authors: yu ey. Clin Cancer Res. 2025 Nov 3;31(21):4393-4395. doi: 10.1158/1078-0432.CCR-25-2546. Clin Cancer Res. 2025. PMID: 40924642 Free PMC article.
Human kallikrein (KLK) 2 is a prostate cancer tissue-specific protein that is regulated by androgen receptor signaling. ...
Human kallikrein (KLK) 2 is a prostate cancer tissue-specific protein that is regulated by androgen receptor signaling. ...
Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: A retrospective cohort study.
Bakaloudi DR, Koehne EL, Voutsinas JM, Diamantopoulos LΝ, Makrakis D, Grivas P, True LD, Tretiakova MS, Vakar-Lopez F, Psutka SP, Holt SK, Gore JL, Lin DW, Schade GR, Nyame YA, Hsieh AC, Yezefski T, Hawley JE, Schweizer MT, Cheng HH, Yu EY, Montgomery RB, Wu QV, Wright JL. Bakaloudi DR, et al. Among authors: yu ey. Urol Oncol. 2025 Dec;43(12):695.e21-695.e29. doi: 10.1016/j.urolonc.2025.07.024. Epub 2025 Sep 2. Urol Oncol. 2025. PMID: 40903320
INTRODUCTION AND OBJECTIVES: Transurethral Resection of Bladder Tumor (TURBT) is a diagnostic staging procedure for bladder cancer (BC). Its pathologic interpretation may be limited by cautery artifact, lack of spatial orientation of tumor specimens, inter-pathologi …
INTRODUCTION AND OBJECTIVES: Transurethral Resection of Bladder Tumor (TURBT) is a diagnostic staging procedure for bladder cancer …
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma.
van der Heijden MS, Powles T, Gupta S, Loriot Y, Galsky MD, Valderrama BP, Sridhar SS, Yu EY, Iyer G, Kikuchi E, Castellano D, Hoffman-Censits J, Drakaki A, Mar N, Maroto Rey JP, Vulsteke C, Arafat W, Duran I, Dawson NA, Swami U, Gorla S, Moreno BH, Yu X, Lu YT, Bedke J. van der Heijden MS, et al. Among authors: yu ey. ESMO Open. 2025 Aug;10(8):105544. doi: 10.1016/j.esmoop.2025.105544. Epub 2025 Aug 11. ESMO Open. 2025. PMID: 40795788 Free PMC article. Clinical Trial.
BACKGROUND: In the phase III EV-302 study (NCT04223856), enfortumab vedotin (EV) plus pembrolizumab (P) demonstrated superior efficacy and safety versus platinum-based chemotherapy in patients with previously untreated locally advanced/metastatic urothelial cancer (la/mUC) …
BACKGROUND: In the phase III EV-302 study (NCT04223856), enfortumab vedotin (EV) plus pembrolizumab (P) demonstrated superior efficacy and s …
280 results